Article Cited by others

INVITED REVIEW

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation

Lipianskaya Julia, Cohen Alexa, Chen Clark J, Hsia Elaine, Squires Jill, Li Zhen, Zhang Yaqun, Li Wei, Chen Xufeng, Xu Hua, Huang Jiaoti

Year : 2014| Volume: 16| Issue : 4 | Page no: 541-544

   This article has been cited by
 
1 3D porous chitosan-chondroitin sulfate scaffolds promote epithelial to mesenchymal transition in prostate cancer cells
Kailei Xu,Zi Wang,John A. Copland,Ratna Chakrabarti,Stephen J. Florczyk
Biomaterials. 2020; : 120126
[Pubmed]  [Google Scholar] [DOI]
2 Ablation of LGR4 signaling enhances radiation sensitivity of prostate cancer cells
Fang Liang,Hao Zhang,Duo Cheng,Hui Gao,Junyong Wang,Junmin Yue,Nan Zhang,Jie Du,Zhaoyang Wang,Beibei Zhao
Life Sciences. 2020; : 118737
[Pubmed]  [Google Scholar] [DOI]
3 Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review
Jing Hu,Bo Han,Jiaoti Huang
Archives of Pathology & Laboratory Medicine. 2020; 144(3): 320
[Pubmed]  [Google Scholar] [DOI]
4 3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines
Kailei Xu,Kavya Ganapathy,Thomas Andl,Zi Wang,John A. Copland,Ratna Chakrabarti,Stephen J. Florczyk
Biomaterials. 2019; 217: 119311
[Pubmed]  [Google Scholar] [DOI]
5 Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
Stephen J. Patel,Stephen J. Chugh,Stephen J. Tripathi
Cancers. 2019; 11(10): 1405
[Pubmed]  [Google Scholar] [DOI]
6 N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
Yu Yin,Lingfan Xu,Yan Chang,Tao Zeng,Xufeng Chen,Aifeng Wang,Jeff Groth,Wen-Chi Foo,Chaozhao Liang,Hailiang Hu,Jiaoti Huang
Molecular Cancer. 2019; 18(1)
[Pubmed]  [Google Scholar] [DOI]
7 HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer
Yi-Ting Chang,Tzu-Ping Lin,Jui-Ting Tang,Mel Campbell,Yun-Li Luo,Shih-Yen Lu,Chia-Pei Yang,Ting-Yu Cheng,Ching-Hsin Chang,Tze-Tze Liu,Chi-Hung Lin,Hsing-Jein Kung,Chin-Chen Pan,Pei-Ching Chang
Cancer Letters. 2018; 433: 43
[Pubmed]  [Google Scholar] [DOI]
8 Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
Lingfan Xu,Junyi Chen,Weipeng Liu,Chaozhao Liang,Hailiang Hu,Jiaoti Huang
Asian Journal of Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
9 ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis
Yuanjie Niu,Changcheng Guo,Simeng Wen,Jing Tian,Jie Luo,Keliang Wang,Hao Tian,Shuyuan Yeh,Chawnshang Chang
Cancer Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing
Anna Schuh,Helene Dreau,Samantha J.L. Knight,Kate Ridout,Tuba Mizani,Dimitris Vavoulis,Richard Colling,Pavlos Antoniou,Erika M. Kvikstad,Melissa M. Pentony,Angela Hamblin,Andrew Protheroe,Marina Parton,Ketan A. Shah,Zsolt Orosz,Nick Athanasou,Bass Hassan,Adrienne M. Flanagan,Ahmed Ahmed,Stuart Winter,Adrian Harris,Ian Tomlinson,Niko Popitsch,David Church,Jenny C. Taylor
Molecular Case Studies. 2018; 4(2): a002279
[Pubmed]  [Google Scholar] [DOI]
11 Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review
Jill B. Feffer,Natalia M. Branis,Jeanine B. Albu
Frontiers in Endocrinology. 2018; 9
[Pubmed]  [Google Scholar] [DOI]
12 Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies,Himisha Beltran,Amina Zoubeidi
Nature Reviews Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
13 TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer
M K Siu,W-Y Chen,H-Y Tsai,H-Y Chen,J J Yin,C-L Chen,Y-C Tsai,Y-N Liu
Prostate Cancer and Prostatic Diseases. 2017;
[Pubmed]  [Google Scholar] [DOI]
14 Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles
David T Hoang,Kenneth A Iczkowski,Deepak Kilari,William See,Marja T Nevalainen
Oncotarget. 2017; 8(2): 3724
[Pubmed]  [Google Scholar] [DOI]
15 MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells
Yi-Cheng Lin,Yi-Ting Chang,Mel Campbell,Tzu-Ping Lin,Chin-Chen Pan,Hsin-Chen Lee,Jean C. Shih,Pei-Ching Chang
Scientific Reports. 2017; 7: 46338
[Pubmed]  [Google Scholar] [DOI]
16 Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer
Jordan OćMalley,Rahul Kumar,Andrey N. Kuzmin,Artem Pliss,Neelu Yadav,Srimmitha Balachandar,Jianmin Wang,Kristopher Attwood,Paras N. Prasad,Dhyan Chandra
Cancer Letters. 2017; 397: 52
[Pubmed]  [Google Scholar] [DOI]
17 CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4
Wei Li,Li Qian,Junhao Lin,Guihai Huang,Nan Hao,Xiuwang Wei,Wei Wang,Jianbo Liang
Oncotarget. 2017; 8(39): 65143
[Pubmed]  [Google Scholar] [DOI]
18 A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector
Zhi Hong Lu,Sergey Kaliberov,Rebecca E. Sohn,Lyudmila Kaliberova,Yingqiu Du,Julie L. Prior,Daniel J. Leib,Anne Chauchereau,Jennifer K. Sehn,David T. Curiel,Jeffrey M. Arbeit
Oncotarget. 2017; 8(7): 12272
[Pubmed]  [Google Scholar] [DOI]
19 Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer
D. S. Mikhaylenko,G. D. Efremov,A. V. Sivkov,D. V. Zaletaev
Molecular Biology. 2016; 50(1): 28
[Pubmed]  [Google Scholar] [DOI]
20 Rapid progression of mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate: A case report
Jingchao Wei,Xiaoping Zheng,Liuxun Li,Wensu Wei,Zhi Long,Leye He
Oncology Letters. 2016; 12(2): 1019
[Pubmed]  [Google Scholar] [DOI]
21 Applications of circulating tumor cells for prostate cancer
Shirley Cheng,Jie-Fu Chen,Yi-Tsung Lu,Leland W.K. Chung,Hsian-Rong Tseng,Edwin M. Posadas
Asian Journal of Urology. 2016; 3(4): 254
[Pubmed]  [Google Scholar] [DOI]
22 Therapy escape mechanisms in the malignant prostate
Frédéric R. Santer,Holger H.H. Erb,Rhiannon V. McNeill
Seminars in Cancer Biology. 2015; 35: 133
[Pubmed]  [Google Scholar] [DOI]
23 Preparation and evaluation of polydopamine imprinting layer coated multi-walled carbon nanotubes for the determination of testosterone in prostate cancer LNcap cells
Xiaoshuang Tang,Wei Liu,Jiaqi Chen,Jing Jia,Zhenkun Ma,Qi Shi,Yang Gao,Xinyang Wang,Shan Xu,Ke Wang,Peng Guo,Dalin He
Anal. Methods. 2015; 7(19): 8326
[Pubmed]  [Google Scholar] [DOI]
24 The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells
Kohei Hashimoto,Yuki Kyoda,Toshiaki Tanaka,Toshihiro Maeda,Ko Kobayashi,Kohsuke Uchida,Hiroshi Kitamura,Koichi Hirata,Taiji Tsukamoto,Naoya Masumori
Laboratory Investigation. 2015;
[Pubmed]  [Google Scholar] [DOI]
25 SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer
Murali Gururajan,Karen A. Cavassani,Margarit Sievert,Peng Duan,Jake Lichterman,Jen-Ming Huang,Bethany Smith,Sungyong You,Srinivas Nandana,Gina Chia-Yi Chu,Sheldon Mink,Sajni Josson,Chunyan Liu,Matteo Morello,Lawrence W. M. Jones,Jayoung Kim,Michael R. Freeman,Neil Bhowmick,Haiyen E. Zhau,Leland W.K. Chung,Edwin M. Posadas
Oncotarget. 2015; 6(42): 44072
[Pubmed]  [Google Scholar] [DOI]
26 Molecular pathways and targets in prostate cancer
Emma Shtivelman,Tomasz M. Beer,Christopher P. Evans
Oncotarget. 2014; 5(17): 7217
[Pubmed]  [Google Scholar] [DOI]

 

Read this article